title: Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities.
abstract: OBJECTIVE
  To determine visceral adiposity (VAT), subcutaneous adiposity (SAT), and regional body adipose differences between HIV-infected and non-HIV-infected subjects in relation to body mass index (BMI) and World Health Organization BMI categories.
  
  
  METHODS
  Analyses were conducted of 306 HIV-infected and 107 community-derived HIV-negative subjects evaluated for metabolic studies between 1999 and 2006. Analyses were stratified by gender. Additional analyses were performed stratifying subjects by metabolic syndrome status.
  
  
  RESULTS
  HIV-infected men and women demonstrated decreased total extremity fat by 1.1 kg and 0.85 kg, respectively, relative to non-HIV-infected control subjects. VAT was increased among HIV-infected men and women in the normal (18.5 to 24.9 kg/m2) and overweight (25.0 to 29.9 kg/m2) categories relative to control subjects but not among those in the obese category (> or =30.0 kg/m2). In contrast, abdominal SAT was reduced among HIV-infected men in the normal and overweight categories but was similar among HIV-infected women and control subjects in these categories. Abdominal SAT was increased among HIV-infected women in the obese category relative to control subjects. Similar results were obtained limiting the analysis to HIV-infected (n = 204) and control subjects (n = 89) without the metabolic syndrome.
  
  
  CONCLUSIONS
  Peripheral lipoatrophy is a consistent finding among HIV-infected men and women with metabolic abnormalities. Relative increases in VAT are most pronounced among male and female HIV-infected subjects in the normal weight and overweight categories. Gender differences in abdominal SAT accumulation are observed, with preservation of SAT among HIV-infected women relative to control subjects.
authors.affiliation: Program in Nutritional Metabolism, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
authors.forename: Tisha
authors.initials: T
authors.lastname: Joy
authors.forename: Hester M
authors.initials: HM
authors.lastname: Keogh
authors.forename: Colleen
authors.initials: C
authors.lastname: Hadigan
authors.forename: Sara E
authors.initials: SE
authors.lastname: Dolan
authors.forename: Kathleen
authors.initials: K
authors.lastname: Fitch
authors.forename: James
authors.initials: J
authors.lastname: Liebau
authors.forename: Stine
authors.initials: S
authors.lastname: Johnsen
authors.forename: Janet
authors.initials: J
authors.lastname: Lo
authors.forename: Steven K
authors.initials: SK
authors.lastname: Grinspoon
mesh_terms: D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001823:Body Composition; D015992:Body Mass Index; D005260:Female; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy*; D006801:Humans; D050152:Intra-Abdominal Fat / Q000002:abnormalities / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D050507:Subcutaneous Fat, Abdominal / Q000002:abnormalities / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents